Support for the Sickle Cell Disease Control Centre

— Guinea —

BACKGROUND

Guinea is one of the countries most severely impacted by sickle cell disease, a very painful hereditary disease that can be fatal if not properly treated (see our section on programmes addressing sickle cell disease, the world’s leading genetic disease). According to statistics published in 2019 by the Donka University Teaching Hospital in Conakry, 20% of the Guinean population is believed to carry the disease. Patients faced with diagnostic challenges and limited access to essential medicines find themselves forced to seek care in other countries in the sub-region, such as Mali, Senegal and Côte d’Ivoire.

IMPROVING TECHNICAL AND HUMAN CAPACITIES

Since 2019, the Fondation Pierre Fabre has been supporting the Sickle Cell Disease Control Centre of the SOS Drépanocytaires Guinée non-profit organisation in Conakry. This medical NGO founded in 2008 offers treatment at moderate cost and holds awareness-raising campaigns, particularly to encourage screening young children, as early treatment helps slow the disease’s progress.

The Foundation’s support is focused on three objectives:

  • Support for staff training and for treatment and transfusion activities (including training in pain management led by the NGO Douleurs sans Frontières);
  • Creation of a medical analysis laboratory (the first medical analyses were performed in November 2020);
  • Opening of a pharmacy centre (including recruitment of a qualified pharmacist).

Other support positions have been identified, including staff to computerise patient medical records.

INCREASE THE NUMBER OF BENEFICIARIES

Throughout 2019, the monthly number of sickle cell medical consultations increased from 334 consultations and 34 new patients in January to 518 consultations and 75 new patients in December.

In 2020, the challenging health and safety context caused various delays, as Guinea is among the African countries most affected by the Covid-19 pandemic. Nevertheless, patient care progressed, with nearly 2,000 consultations between May and September 2020.

KEY FACTS
_____

Priority
Combating Sickle cell disease

Programme
2019-2022

Type of involvement

Objectives

  • Reinforce the centre’s technical capabilities
  • Guarantee the financial independence of the structure
  • Support staff training (activities related to treatment and transfusion)
  • Create a medical laboratory and a pharmacy hub

THE LATEST PROGRESS
_____

Project outcomes
A significant increase in clinical activity in three years: 6,000 patients, double the number of annual consultations.
The support phase enabled us to validate the self-sufficient economic model drawn up by the centre, which recently received official recognition from the Ministry
of Health as a reference centre for sickle-cell disease in Guinea.

A new phase of support
Validated in late 2022, the new phase of support for the CLD will get underway in 2023: it covers the challenges related to decentralisation of access to healthcare in two regions with high prevalence rates as well as support for the implementation of a strategic plan for combating the disease.

ACHIEVEMENTS AND FUTURE INITIATIVES

Achievements

4,071
consultations in 2020

1,086
hospitalisations in 2020

1,963
patients in the active queue

An economic model well-suited to the context

The Sickle Cell Disease Control Centre in Conakry is based on an economic model of self-sufficiency: medications are billed to patients at a price 15% lower than what is charged in private pharmacies and are delivered to the poorest patients free of charge. The resulting revenue makes it possible to pay staff at a level aligned with the country’s standards.

PARTNERS

  • SOS Drépanocytaires Guinée, a non-profit organisation founded in 2008 and approved by the Ministry of Health
  • Sickle Cell Disease Control Centre in Conakry (work completed in 2018)
  • The Douleurs sans Frontières NGO

See also

See also

Screening and management of sickle cell disease

The long-term objective is to sensitise governments to the benefits of a national programme combatting sickle cell disease, and having a viable and adaptable disease management model.

30/07/2018

Follow our actions